Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Lysozyme Goat Milk in Stem Cell Transplant Recipients
NCT04177004Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human lysozyme goat milk in graft-versus-host disease (GVHD) (2 arms), sponsored by City of Hope. Primary endpoints: Patients' ability to drink the specified daily amount of 750 ml human lysozyme goat milk up to 28 days, Unacceptable toxicity up to 28 days and 2 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
human lysozyme goat milk
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04177004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177004.